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Opening Statement
There were several reasons why I chose to obtain a Doctorate of Nursing Practice (DNP) degree. The main reasons were to learn and develop great clinical skills, to be able to promote health, to build long and lasting relationships with my patients and their families and to be able to work with other people to promote real change in our healthcare system. I have always been interested in pathophysiology and clinical practice. I have a great interest in not just what happens to people when they get sick but to truly understand the relationship between humans and health.
My primary goal for my DNP scholarly practice would be to get the training necessary to be able to provide the best care possible for my patients. Not only would I get the clinical exposure to learn how the different diseases affect people and how to diagnose and treat those diseases, I will also be prepared to critique healthcare research in order to incorporate scientific evidence into patient care that will maximize the scope of my practice and optimally care for my patients. Project Plan Process -An evidence-based PCV13 vaccination protocol based on the CDC guidelines using the Provus Discrepancy Evaluation Model as a framework was implemented.
NPs were educated on indications for PCV13 vaccinations and a questionnaire to identify those patients who qualified. Qualified patients were either vaccinated or referred elsewhere for vaccination. The EMR system was reviewed to determine the number of patients who qualified for the PCV13 vaccination who were screened.
Results: Of the 3,202 patients, 4-6% qualified for the PCV13 vaccination, 27.7% were identified and offered the PCV13 vaccination and 11% were vaccinated or referred elsewhere for vaccination. Regarding age, 65.2% of patients who qualified for PCV13 were ≥65 in contrast to 34.8% who were 19-64 years old. As for those patients who were actually vaccinated, 76.5% were ≥65 while 23.5% were 19-64 years old.
Conclusions/Implications -Retail health care clinics can be an effective venue for providing essential vaccinations. Nurse practitioners are well prepared with the knowledge base and skill set to assume a leadership role in the development of vaccination programs within our communities.
Introduction
Public health initiative programs have been extremely successful resulting in the eradication of several very dangerous communicable diseases such as smallpox, diphtheria and polio by the use of vaccinations (Center for Disease Control and Prevention, 1999) . Childhood vaccinations have succeeded in decreasing childhood mortality for those over a year old by 99% (Center for Disease Control and Prevention, 1999) . However, the success rate has not been replicated with adult immunizations. Despite an aggressive campaign by the CDC to increase adult immunization rates, they still remain very poor for all vaccinations (CDC/NCHS, 2014, Table 75 ).
Background and Significance
Incidence of Pneumococcal Disease Streptococcus Pneumoniae (Pneumococcus) was first isolated by Dr. Louis Pasteur in 1881. In the 1940's, penicillin was discovered and the medical community thought they had a tool to eradicate Streptococcus Pneumoniae. However, it was discovered that many patients with invasive Pneumococcal disease (IPD) still died despite antibiotic treatment, especially the elderly ≥65 years old (Plouffe et al., 1996) , the young (<2 years old) and those with immunocompromised states (Hamborsky & Kroger, 2015) . IPD (pneumonia, bacteremia and meningitis) results in significant morbidity and mortality. Pneumococcal pneumonia makes up >400,000 hospitalizations a year with a case fatality rate 5% to 7% which may be much higher among elderly persons. There are also >12,000 cases of Pneumococcal bacteremia without pneumonia a year with a case fatality rate of 20% but may be as high as 60% for the elderly. The most severe IPD is Pneumococcal meningitis. There are 3000 -6000 cases of Pneumococcal meningitis a year with a case fatality rate of 8% among children and 22% among adults (Hamborsky & Kroger, 2015) .
The first Pneumococcal vaccine was licensed in the United States in 1977 with a 14-valent polysaccharide vaccine. In 1983, a 23-valent polysaccharide vaccine was licensed called PPSV23 (Pneumovax). PPSV23 has been found to be highly effective against IPDs in young adults. However, its efficacy is markedly decreased in the elderly ≥65 years old (Plouffe et al., 1996) , and the young (<2 years old) (Hamborsky & Kroger, 2015) . The first conjugate Pneumococcal vaccine was not licensed until 2000 with a 7-valent polysaccharide conjugate vaccine (PCV7) which was then replaced with a 13-valent Pneumococcal conjugate vaccine licensed in 2010 (Tomczyk, et al., 2014) .
While data on immunocompromised patients are lacking, PCV13 has been shown to be 75% effective in preventing IPDs, and 45% effective at preventing non-invasive pneumonia caused by the 13 strains it covers. PPSV23 has been shown to be 60 to 70% effective in preventing invasive disease caused by the 23 strains it covers (Bonten et al., 2015) . Furthermore, it has been shown that an initial PCV13 vaccination enhances the protective effects of PPSV23 for most of the serotypes that are found in both vaccines whereas a dose of PPSV23 prior to PCV13 vaccination did not (Greenberg et al., 2014) . Table 75 ). This is well below the Healthy People 2020 goal of 90% coverage with the Pneumococcal vaccines for patients ≥65 years old (Hamborsky & Kroger, 2015) .
There are many barriers to adult vaccinations. Only approximately 30% of general internists or family physicians report that they assess their patients' vaccination status at every visit (Hurley et al., 2014) . Information systems can be helpful to track vaccinations but only 8% of general internists and 36% of family physicians use those (Hurley et al., 2014) . Another barrier is the lack of vaccines themselves at the clinics. Due to financial constraints (lack of insurance coverage, inadequate reimbursements and lack of a VFC type program for adults), most primary care providers do not stock all the recommended vaccines and instead refer patients to get those vaccinations at a local pharmacy or at the public health department (Hurley et al., 2014) . Finally, 50% of general internists and family physicians report management of acute problems taking precedence over vaccinations (Hurley et al., 2014) .
Pneumococcus is one of the four major vaccine preventable diseases in the United States for those ≥65 years of age along with influenza, herpes zoster and pertussis. While Pneumococcal diseases only contribute to 8% of the incidence of disease ranking it third highest incidence compared to the other three, it contributes to 25% of the total healthcare utilization of these four diseases which sets it second in healthcare utilization behind only influenza (Figure 1 ) (McLaughlin, McGinnis, Tan, Mercatante, & Fortuna, 2015) .
Retail Healthcare Clinics
Retail healthcare clinics started in 2000. These clinics are general staffed by NPs or PAs and focus on convenient care for minor illnesses as well as vaccinations. The advantages of retail health clinics are price and convenience. A comparison between the average costs of common illnesses treated at a retail healthcare clinic vs. physicians' offices vs. urgent care centers vs. emergency departments were $110 vs. $166 vs. $156 vs. $570 respectively ). Furthermore, an estimated 10.6% of the total U.S. and 13.4% of the urban U.S. population lives within a five minute driving distance of a retail healthcare clinic (Rudavsky, 2009 The three largest retail healthcare clinics make up 81% of all retail healthcare clinics in the United States . In 2009, 40% of these retail healthcare clinic visits provided immunizations for 1.95 million visits resulting in 1.8 million influenza (including H1N1) vaccinations and almost 60,000 Pneumococcal vaccinations (Uscher-Pines, 2012) . This same study reviewed data from the two largest healthcare clinic chains (accounting for 76% of all retail health clinic visits) and discovered that Pneumococcal vaccinations for those ≥65 and those 19-64 with high risk for Pneumococcal infections accounted for only 0.6% each of these total visits or 1.2% of the total clinic visits for these two retail healthcare chains (Uscher-Pines, 2012).
Purpose of Project
The purpose of this evidence-based practice project was to implement a PCV13 vaccination protocol in the Palomar retail healthcare clinic system. Prior to this project, there was no PCV13 vaccination program in this retail healthcare system.
Theoretical Model
The Provus Discrepancy Evaluation Model was used as a framework for this project (Provus, 1969) Those who declined the vaccinations on that date or chose not to receive the vaccinations at the clinics were either given another appointment to receive the vaccinations or referred to their PCP or a local pharmacy for the vaccinations. The most common reason for referral to a local pharmacy was with Medicare patients as the clinic did not accept Medicare insurance whereas the vast majority of the local pharmacies did.
Advertisement flyers for PCV13 were made available in the clinics for all patients to view and copies were given to them on request (Appendix D). Name badges with the logo "ask me about the new pneumonia vaccine" which also had an insert with the prices for the vaccinations for all the insurances the clinic accepted as well as the self-pay price were given to the NPs to wear. Completed patient questionnaires were stored in a clipboard in the clinic and picked up weekly by the project director for data analysis. The data were then entered into a data collection sheet (Appendix E) for analysis.
Evaluation of Benchmarks
The objective of this program was to implement a protocol for identification and administration of the PCV13 immunization to all adults ≥65 years old as well as adults 19-64 years of age with certain immunocompromised states that make them high risk for IPDs. The goal was to demonstrate that it is feasible for retail healthcare clinics to provide this service for older adult patients. The benchmarks were (1) to offer the PCV13 vaccination to a minimum of 20% of those eligible, and (2) to administer PCV13 vaccinations, or refer elsewhere for vaccination, to a minimum of 10% of those eligible based on CDC guidelines.
Cost/Benefit Analysis
The cost of the PCV13 vaccination to our clinic system was $128.40 (the purchase occurred in ten vial packs costing $1284). The reimbursement for the vaccine ranged from $145 to $180 depending on insurance. For those without insurance, a charge of $160/vaccination was incurred which is less expensive than the local pharmacies which averaged approximately $200/vaccination. For those with insurance that was not accepted at the retail healthcare site, a referral was made to their PCP or a local pharmacy for the vaccination depending on their insurance and preference. On average, the clinic made a profit of $30/vaccination.
The benefits of PCV13 vaccination are in decreased healthcare costs and a healthier population. The Quality adjusted life years (QALY) for PCV13 is estimated at $28,900 QALY compared to $34,600 QALY for PPSV23 (Smith et al., 2012) . These calculations do not take into account herd immunity. It is still not known at this time whether PCV13 will have a similar herd immunity effect that was seen with PCV7. If so, the benefits of PCV13 may be even higher.
It is also estimated that giving the PCV13 vaccination based on current recommendations to those ≥65 and high risk patients 19-64 will decrease the incidence of IPDs from 858 to 833/100,000, decrease the deaths from pneumonia from 1775 to 1749/100,000 and decrease hospitalizations for Non-Pneumococcal pneumonia from 9292 to 9122/100,000 (Smith et al., 2012) . This would result in 25 less incidence of IPDs, 26 fewer deaths and 170 fever hospitalizations for non-Pneumococcal pneumonia/100,000 patients vaccinated.
Results
Data analysis extending over the four-month period including November and December 2015 extending through January and February 2016 revealed that 4.3%, 3.8%, 5.9% and 5.3% of the total patients seen in the clinic system qualified for the PCV13 vaccination with an average of 4.8% (Figure 4 ). During these 4 months a total of 936, 610, 732 and 924 patients were seen in the Palomar Expresscare system for a total of 3202 patient encounters (Table 1) . In November, there were 40 patients eligible for the vaccination, 9 of those were offered the vaccination, 8 of which declined and 1 person was vaccinated. In December, there were 23 eligible patients, 5 were offered vaccination all of whom declined. In January, 43 patients were eligible, 17were offered the vaccine, 8 declined, 8 were referred elsewhere for vaccination and one patient made a follow-up appointment for vaccination. In February, there were 49 eligible patients, 12 were offered the vaccine, 5 declined, 2 were vaccinated and 5 were referred elsewhere for vaccination (Figure 2 ). For the 4 months of the study, 31, 18, 26 and 37 eligible patients were not identified and offered PCV13 vaccination (Figure 2 ).
Of those eligible patients, there were 101 patients ≥65 years old compared to 54 patients who were 19-64 years old with high risk for Pneumococcal infections. This resulted in 65.2% of those eligible for PCV13 being ≥65 compared to 34.8% for those 19-64 years old. Furthermore, those ≥65 were more willing to get the PCV13 vaccination with 76.5% of those who were vaccinated or referred elsewhere for vaccination being ≥65 and only 23.5% being 19-64 years old (Table 1) . This can also be seen based on the percentages of eligible patients vaccinated by age group and month (Figure 3 ). Table 75 ). As adult PCV13 vaccination recommendations are new, there is not sufficient data to establish a current benchmark vaccination rate however it is generally accepted that it is lower than even the abysmal vaccination rates for PPSV23. 
Figure 4 -% of patients eligible and ultimate vaccination results
Retail healthcare clinics are becoming increasingly common affording adult community residents easy access to primary care including vaccinations (Rudavsky, 2009) . Since NPs make up a majority of the staff for these retail healthcare clinics , we have an opportunity to improve the health of not only our patients but to the US healthcare system. As such, NPs should assume leadership roles in developing vaccination protocols. Vaccination protocols can also provide good financial revenue for these retail healthcare clinics (UscherPines, 2012) along with providing a service that the current primary care system has clearly shown itself incapable of effectively providing (Hurley et al., 2014) . With our retail healthcare system vaccination project, approximately 4% to 6% of the patients seen qualify for PCV13
vaccination. This represents a significant vaccination opportunity for providers to give their patients an important vaccination. does show that the retail healthcare clinic system can be an effective venue for improving the PCV13 vaccination rate.
Insurance funding was a significant barrier for our clinics. The clinics in this project did not accept Medicare which limited the number of eligible participants to receive vaccinations.
These patients were referred to their PCP or to a pharmacy for vaccination. Due to this challenge, Expresscare is currently considering adding Medicare coverage for our clinics.
Another barrier in this project was the continued emphasis on acute illnesses and failure to incorporate more preventative care. As the healthcare system increasingly moves toward increasing use of electronic medical records (EMR), it can be a valuable resource for enhancing primary care. One of the initial intentions for this project was to incorporate a vaccination reminder and the questionnaire into our EMR system which unfortunately did not happen due to technical problems. This would have improved our project as well as possibly counteracted our slow start for the project. At this time, the Expresscare clinic system is still looking into incorporating the changes to our EMR system for long term sustainability beyond the scope of this project.
Concluding Essay
Nurses have been integral to the healthcare system for a long time and their roles are fairly well defined and understood by consumers of healthcare. However, as nurses continue to expand their roles, there are increasing uncertainties as to the multiple and varied roles of nurses.
The roles and responsibilities of APRN's (Advanced Practice Registered Nurses) are to improve the health of their patients and to promote healthcare as a whole. An APRN improves the health of their patients by providing excellent clinical care through critical appraisal of new data to incorporate into patient care while navigating the complex healthcare system. An APRN, specifically a nurse practitioner, must be more than just a great clinician. In order to promote overall improvements in healthcare, APRNs must care for their patients as well as the "dynamics" of healthcare. This requires skills in organizational and systems leadership, healthcare policy and advocacy, and improving inter-professional collaboration with other members of the healthcare field not just for themselves but for APRNs in general.
The roles of doctoral prepared APRNs are not well understood, mostly due to a lack of understanding and experience of working with APRNs who hold a doctorate. Most people both inside and outside of the healthcare field do not know our roles well because they have not had sufficient exposure to us and our skill sets to really understand what we bring to the table. As our numbers grow and we become more involved in healthcare this lack of understanding should lessen. As APRNs get more involved in providing healthcare and patient advocacy, we will be better understood as a profession. Doctoral APRNs are on the forefront of expanding traditional roles of nursing and assuming leadership roles in clinical decision making that is integral to patient care delivery.
practitioner. I highly value the training that I received on critical appraisal of the evidence and I plan to use it directly on patient management decisions. While there is also a great need out there for nurse practitioners to take leadership roles in forming policy; that need will have to be filled by my colleagues. I do not know exactly what setting it will be yet but my future is going to involve direct patient care. I value the time that I spend with my patients face to face and plan to care for those who need me as long as I possibly can.
